Aspasia S.
- Country
- France
- Department
- Département d'hématologie
Research Overview
- Evaluation of Luspatercept and Epoetin Alfa in Low-Risk Myelodysplastic Syndromes Without Ring Sideroblasts Post-Erythropoiesis-Stimulating Agent Failure
- Evaluation of ASTX727 and Donor Lymphocyte Infusions Post-Allogeneic Stem Cell Transplantation in High-Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia
- Phase I/II Open-Label Study of Azacitidine and Venetoclax in Untreated Higher-Risk Myelodysplastic Syndromes Ineligible for Allogeneic Transplantation
Data & Insights
Has run more than one trial at 38 of 68 partner sites.
Specializations
Myelodysplastic Syndromes Research
The investigator specializes in treating various forms of myelodysplastic syndromes (MDS), with particular focus on both higher-risk and lower-risk variants. Their research encompasses novel therapeutic approaches for patients with specific genetic mutations, including IDH1 and IDH2 mutations.
- Higher-risk MDS treatment strategies
- Novel combination therapies
- Genetic mutation-targeted approaches
Hematologic Malignancies
The investigator conducts research in various blood cancers, including Classical Hodgkin Lymphoma and Chronic Myelomonocytic Leukemia (CMML). Their work extends to post-transplantation care and innovative treatment combinations for these conditions.
- Advanced treatment protocols
- Post-transplantation therapy
- Combination treatment approaches
Therapeutic Innovation
The investigator explores innovative treatment combinations including venetoclax-based therapies and immunotherapy approaches. Their research includes evaluation of novel agents for various hematologic conditions and optimization of existing treatment protocols.
- Immunotherapy applications
- Novel drug combinations
- Treatment optimization strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.